Active Biotech Interim Report Q3 2023
THIRD QUARTER IN BRIEF
- Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
- Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
- Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (September 13)
EVENTS AFTER THE END OF THE PERIOD
- Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023 (November 2)
- The board of directors resolved on November 9, based on the authorization from the general meeting, to carry out a rights issue of approximately SEK 51 million (before issue costs) to secure financing of the ongoing and planned development programs for tasquinimod and laquinimod
FINANCIAL SUMMARY
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2023 2022 | 2023 2022 | 2022 | |||
| Net sales | – | – | – | – | – |
| Operating profit/loss | -10.6 | -13.4 | -33.7 | -42.6 | -57.9 |
| Profit/loss after tax | -10.6 | -13.4 | -33.3 | -43.4 | -58.4 |
| Earnings per share (SEK) | -0.04 | -0.06 | -0.13 | -0.19 | -0.25 |
| Cash and cash equivalents (at close of period) | 5.6 | 55.0 | 41.8 | ||
The report is also available at www.activebiotech.com